US 12,343,318 B2
Use of compound or medicinal derivative thereof in inhibiting AIM2 protein activity
Qi Zhen, Hefei (CN); Weiwei Chen, Hefei (CN); Zhuo Li, Hefei (CN); Yirui Wang, Hefei (CN); and Liangdan Sun, Hefei (CN)
Assigned to Liangdan Sun, Hefei (CN)
Filed by Liangdan Sun, Hefei (CN)
Filed on Apr. 10, 2023, as Appl. No. 18/298,012.
Claims priority of application No. 202310207413.6 (CN), filed on Mar. 1, 2023.
Prior Publication US 2024/0299315 A1, Sep. 12, 2024
Int. Cl. A61K 31/122 (2006.01); A61P 17/06 (2006.01)
CPC A61K 31/122 (2013.01) [A61P 17/06 (2018.01)] 10 Claims
 
1. An application method of a compound or a pharmaceutically acceptable salt thereof, comprising:
administering the compound or the pharmaceutically acceptable salt thereof to patients with psoriasis at a target dose to thereby inhibit absent in melanoma 2 (AIM2) protein activity by using the compound or the pharmaceutically acceptable salt thereof, wherein the compound is as shown in a formula I, and the formula I is expressed as follows:

OG Complex Work Unit Chemistry
wherein the target dose of the compound or the pharmaceutically acceptable salt thereof to inhibit the AIM2 protein activity of HaCaT cells is 10 micromoles per liter (uM).